RxDoctor Payments Data

Natasha Burch

Family · North Platte, NENPI 1649915000

Payments from drug & device makers

$495in general payments, 2019–2025

Across 21 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$286
  • Regeneron Healthcare Solutions, Inc.$72
  • Verona Pharma, Inc.$47
  • AbbVie$28
  • Boehringer Ingelheim$18
  • Sanofi$17
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$495 in reported general payments places this provider in the 60th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$2,005
Medicare patients
26
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter156$108,340
Stiolto RespimatTiotropium Br/Olodaterol Hcl82$41,271
Breo ElliptaFluticasone/Vilanterol73$30,373
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$26,360
Spiriva RespimatTiotropium Bromide42$21,848
Bevespi AerosphereGlycopyrrolate/Formoterol Fum51$20,992
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$18,718
Incruse ElliptaUmeclidinium Bromide43$15,346
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate48$9,641
Advair HfaFluticasone Propion/Salmeterol26$9,139
Albuterol Sulfate HfaAlbuterol Sulfate267$8,225
Ventolin HfaAlbuterol Sulfate86$5,006
SymbicortBudesonide/Formoterol Fumarate20$4,471
Arnuity ElliptaFluticasone Furoate19$3,843
DuleraMometasone/Formoterol11$3,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$18$63,118124 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$286$51,824115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 809 family providers in Nebraska.

Other family in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →